Fytexia sharing new research on satiety weight-management ingredient at SupplySide West

October 31, 2018

Fytexia will introduce new data at SupplySide West 2018 on its weight-management satiety ingredient DNF-10. 

Fytexia (Verdres, France) will introduce new data at SupplySide West 2018 on its weight-management satiety ingredient DNF-10. A selection of peptides from Saccharomyces cerevisiae (Brewer’s yeast), DNF-10 has been clinically proven for weight management by enhancing satiety and reducing food intake. In a press release, Fytexia explains that DNF-10 regulates mediators of satiety by lowering the hypothalamic expression of neuropeptide Y and downregulating the hunger-promoter ghrelin. Over the long term, the release states, DNF-10 also modulated the secretion of leptin, which is a satiety hormone secreted by fat cells. 

There are currently four published clinical studies on a total of 135 subjects that support these claims. The most recent study was published in 2017 by Preventative Nutrition and Food Science1. This particular study tested the ingredients’ ability at a low dose of 500 mg/day. In that study, 30 obese women were randomly assigned to receive either DNF-10 or placebo for eight weeks. Results showed that following those eight weeks, the women taking DNF-10 lost a significant amount of body weight compared to baseline and showed a significant reduction in calorie intake. By comparison, the control group wanted to each much more food, thought about food more often, and also showed a slight increase in preference for sweets, while the DNF-10 group showed a significant reduction in cravings for sweetness.

DNF-10 is water soluble and heat resistant, with a recommended dose of 500 mg/day for formulating dietary supplements and functional foods, says the company.

References:

1. Jung EY et al. “Low dose yeast hydrolysate in treatment of obesity and weight loss.” Preventative Nutrition and Food Science, vol. 22, no 1 (2017): 45-49